Photo: "Lidocaine HCl" by JL Johnson // User47.com, BY-SA via Openverse

What to know about the $5 billion Global Fund shortfall hitting just as HIV prevention science peaks

Global health officials meeting at the AIDS 2026 conference in Rio de Janeiro this week are confronting a timeline problem: the tools to end AIDS as a public health threat arrived at almost the exact moment the machinery to deliver them was taken apart.

The Global Fund to Fight AIDS, Tuberculosis and Malaria is now reviewing funding proposals for its next three-year cycle roughly $5 billion short of the target it set last December, according to Mitchell Warren, executive director of the HIV prevention advocacy group AVAC, who discussed the shortfall in an interview with Managed Healthcare Executive ahead of the conference. Some countries have already been told, per Warren, that the upcoming cycle will be their last round of Global Fund support — and at a reduced amount. That timeline detail matters beyond this funding cycle alone: replenishment gaps of this size don't just delay programs, they force health ministries to choose which prevention services survive and which get cut, decisions that took effect months before any drug approval could reach the clinics losing funding to distribute it.

The gap traces back to a specific administrative event, not just a budget line. At the start of 2025, the Trump administration dismantled the U.S. Agency for International Development, which had implemented much of the President's Emergency Plan for AIDS Relief (PEPFAR) — the program responsible for a large share of global HIV prevention infrastructure. Warren said PEPFAR funds still reaching community prevention programs now come curtailed or restricted, and that transparency around U.S. HIV program data has declined. That erosion sits awkwardly next to a separate claim from the same administration: it has touted a 50% increase in its commitment to scale up lenacapavir for pre-exposure prophylaxis, according to Warren's account — a stated expansion in one drug's funding running alongside a contraction in the broader system that would deliver it and track the results.

The science side of the ledger looks almost unrecognizable from a few years ago. Warren said conference attendees can expect data on MK-8527, Merck's investigational once-monthly oral PrEP pill, and on a longer-acting treatment pill combining islatravir and lenacapavir; researchers presented positive phase 3 results from that combination at a July 21 press conference ahead of formal conference presentation. Reduce the dosing burden to once a month, or extend treatment intervals, and you remove two of the biggest reasons people drop off HIV prevention and treatment regimens — friction that community health programs used to help absorb. That's precisely the layer of infrastructure now thinnest: it isn't the lab work being defunded, it's the last-mile system that turns a pill into a completed regimen for someone hundreds of miles from a well-resourced clinic.

Warren's phrase for the moment — a "cruel irony" — is doing real work here: strong science does not automatically translate into impact if the transport, staffing and country-level financing to deliver it are gone. What plays out at the Global Fund's board table in the coming months, and in the country notices already going out, will determine whether the 2026 pipeline reaches patients on anything like the timeline its trial data suggests is possible.